Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2011 September 1; 121(9): 3756–3762.
Published online 2011 August 8. doi:  10.1172/JCI45194
PMCID: PMC3163947

Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice


Lithium is the first-line therapy for bipolar disorder. However, its therapeutic target remains controversial. Candidates include inositol monophosphatases, glycogen synthase kinase-3 (GSK-3), and a β-arrestin-2/AKT/protein phosphatase 2A (β-arrestin-2/AKT/PP2A) complex that is known to be required for lithium-sensitive behaviors. Defining the direct target(s) is critical for the development of new therapies and for elucidating the molecular pathogenesis of this major psychiatric disorder. Here, we show what we believe to be a new link between GSK-3 and the β-arrestin-2 complex in mice and propose an integrated mechanism that accounts for the effects of lithium on multiple behaviors. GSK-3β (Gsk3b) overexpression reversed behavioral defects observed in lithium-treated mice and similar behaviors observed in Gsk3b+/– mice. Furthermore, immunoprecipitation of striatial tissue from WT mice revealed that lithium disrupted the β-arrestin-2/Akt/PP2A complex by directly inhibiting GSK-3. GSK-3 inhibitors or loss of one copy of the Gsk3b gene reduced β-arrestin-2/Akt/PP2A complex formation in mice, while overexpression of Gsk3b restored complex formation in lithium-treated mice. Thus, GSK-3 regulates the stability of the β-arrestin-2/Akt/PP2A complex, and lithium disrupts the complex through direct inhibition of GSK-3. We believe these findings reveal a new role for GSK-3 within the β-arrestin complex and demonstrate that GSK-3 is a critical target of lithium in mammalian behaviors.


Bipolar disorder (BPD) is a potentially devastating affective disorder affecting 1%–2% of the population worldwide (1). Lithium has remained the first line of therapy for decades (24), and yet the molecular target of lithium in BPD remains highly controversial (5). The leading candidates under active investigation as potential therapeutic targets of lithium include inositol monophosphatases and related phosphomonoesterases (611), glycogen synthase kinase-3 (GSK-3) (12), and the scaffolding function of β-arrestin-2 (13).

GSK-3 has emerged as a strong candidate for the relevant in vivo target of lithium. Lithium inhibits GSK-3 in vitro (12) and in vivo at therapeutically relevant concentrations (1420). Inhibition of GSK-3 provides a compelling explanation for the effects of lithium on the development of diverse organisms (8), and these observations are supported by pharmacologic (2123) and genetic loss-of-function approaches that closely mimic lithium effects on development (8, 2429). Systemic lithium inhibits GSK-3 in the mouse brain (16, 20, 30, 31) and in peripheral blood cells of patients with BPD (32, 33). Genetic loss of function and inhibition of GSK-3 with structurally diverse inhibitors also parallel lithium effects in diverse behaviors in rodents (13, 20, 3437). These correlations support GSK-3 as the relevant target of lithium in mammalian behavior.

However, the specificity of lithium action in these settings has not been assessed by rescue experiments to demonstrate a causal role for GSK-3. Furthermore, elegant recent work suggests that behavioral effects of lithium arise through inhibition of the scaffolding function of β-arrestin-2 that mediates interaction of Akt and protein phosphatase 2A (PP2A) to regulate Akt (acting upstream of GSK-3) (13, 38). To test whether lithium-mediated behavioral effects are specifically due to inhibition of GSK-3, we have generated transgenic mice that overexpress GSK-3β (Gsk3b) in the brain and show that Gsk3b overexpression reverses the effects of lithium in multiple behaviors. Using Gsk3b gain-of-function and loss-of-function approaches, we also show that GSK-3 is required for stability of the β-arrestin-2/Akt/PP2A complex and that direct inhibition of GSK-3 disrupts the β-arrestin-2 complex in vivo. Taken together, these findings reconcile 2 leading hypotheses for lithium action and provide strong support for GSK-3 as an essential direct target of lithium in mammalian behaviors.


Overexpression of Gsk3b reverses lithium-sensitive behaviors.

Rescue of a gene knockout or drug-induced phenotype by restoring activity of the putative target provides strong support for the hypothesis that the phenotype is due to specific inhibition of the target. This is considered an essential control in the genetic analysis of model organisms, such as yeast and fruit flies, although it is less often applied in mammalian systems. We therefore tested whether transgenic expression of Gsk3b in the brain would reverse lithium-sensitive phenotypes, including established lithium-sensitive behaviors (20) and assembly of the β-arrestin-2/Akt/PP2A complex (13). Initially, we tested whether increasing GSK-3 levels would reverse inhibition of substrate phosphorylation in the presence of lithium chloride (LiCl) in vitro. Raising the overall level of GSK-3 protein by 50% restored substrate phosphorylation in the presence of LiCl to that of control levels in vitro (Supplemental Results and Supplemental Figure 1A; supplemental material available online with this article; doi: 10.1172/JCI45194DS1). Gsk3b overexpression also restored lithium-inhibited phosphorylation of the endogenous GSK-3 substrate glycogen synthase in human embryonic kidney cells (Supplemental Results and Supplemental Figure 1B) and reversed activation of a Wnt-dependent transcription reporter (similar to TOPFLASH) that was robustly activated by lithium (Supplemental Results and Supplemental Figure 1C). Thus, increasing GSK-3 levels reversed lithium effects in vitro and in cultured cells. We next tested whether transgenic expression of Gsk3b in the brain rescues lithium-sensitive behaviors in mice.

Chronic lithium treatment reduces immobility in the forced swim test (FST), reduces exploratory behavior, and increases time in the open area of the elevated zero maze (EZM) (20). These parallels between lithium action and Gsk3b loss of function are consistent with the hypothesis that GSK-3 is the relevant target of lithium in these behaviors, but to establish a causal role for inhibition of GSK-3 by lithium, we tested whether overexpression of Gsk3b would reverse the behavioral effects of lithium. The mouse prion promoter (MoPrp) drives transgene expression in neurons and glia throughout the central nervous system of mice (39). This promoter was used to drive expression of Gsk3b with a C-terminal 6X-his tag (Figure (Figure1A).1A). Two transgenic founder lines were obtained (PrpGsk3bL56 and PrpGsk3bL64) and were backcrossed into the C57BL/6 background. Expression of the transgene in cortex, hippocampus, amygdala, hypothalamus, striatum, nucleus accumbens, and cerebellum was confirmed by RT-PCR (data not shown) and by Western blot. GSK-3β-his was detected in all brain regions tested, with PrpGsk3bL56 mice showing higher GSK-3β-his expression compared with that of PrpGsk3bL64 mice (Figure (Figure1B).1B). Increased GSK-3β protein expression was confirmed by Western blotting with antibodies that recognize the GSK-3β N terminus (Figure (Figure1C)1C) or a C-terminal epitope conserved in GSK-3α and GSK-3β (Figure (Figure1D);1D); increased GSK-3β protein expression was also confirmed by LI-COR imaging, which showed a 30% increase in overall GSK-3β protein in the cortex of PrpGsk3bL56 mice. A higher-mobility his-tagged band observed in all transgenics (Figure (Figure1B)1B) also reacted with the C-terminal GSK-3 antibody (Figure (Figure1D),1D), and a similar band at lower intensity was also observed in WT brain extracts, consistent with partial N-terminal proteolysis, which may represent endogenous calpain-mediated cleavage, as reported previously (40, 41), although we cannot rule out partial proteolysis during sample preparation. The PrpGsk3b mice also demonstrated increased GSK-3 activity in lysates prepared from striatum and cortex (Supplemental Methods, Supplemental Results, and Supplemental Figure 2). Coordination, overall activity in the open field (Supplemental Results and Supplemental Figure 5), and the general state of Gsk3b transgenic mice were indistinguishable from those of their WT littermates, indicating no overt physiological or behavioral state changes in Gsk3b-overexpressing mice.

Figure 1
Expression of Gsk3b-his in mouse brain.

In the FST, mice are placed in a cylinder partially filled with water, and the time that the mouse remains immobile is measured in the last 4 minutes of a 6-minute test (42). To investigate whether the effects of lithium on the FST are reversed by overexpression of Gsk3b, we tested WT and PrpGsk3b mice, with and without lithium treatment. In the absence of lithium treatment, there was no effect of Gsk3b overexpression. A 1-way ANOVA on the FST data revealed a robust effect of lithium in WT mice (P < 0.01), as described previously (20, 43). In contrast, the effect of lithium was blocked in Prp­Gsk3bL56 mice, indicating that Gsk3b overexpression rescues this effect of lithium (Figure (Figure2A).2A). There was no significant effect of Gsk3b overexpression in PrpGsk3bL64 mice, which may reflect the relatively lower level of GSK-3β-his expression in these mice (Figure (Figure1B). 1B).

Figure 2
Overexpression of Gsk3b reverses the behavioral effects of lithium.

In the EZM, mice are placed on a circular track with 2 symmetrically opposed open and enclosed areas, and the time spent in the open versus the closed arms is measured. As shown previously (20), lithium treatment increased time in the open areas, and overexpression of Gsk3b reversed this effect in both transgenic lines (P < 0.05), restoring time spent in the open area to that of WT control levels (Figure (Figure2B).2B). These observations are consistent with and complementary to the recent observation that knockin of phosphorylation-defective forms of GSK-3α and GSK-3β, which prevents inhibitory phosphorylation at N-terminal serines, increases time in the open area of the elevated plus maze (33).

Hole poke exploratory behavior measures the frequency at which mice explore holes in the floor of an observation chamber. Chronic lithium reduces the number of hole pokes without affecting overall activity (20). Consistent with previous findings, lithium reduced hole pokes in WT mice (P < 0.05). Overexpression of Gsk3b restored the number of hole pokes in lithium-treated PrpGsk3bL56 mice to those of WT control levels (Figure (Figure2C);2C); lithium-treated PrpGsk3bL64 mice also showed an increase in the number of hole pokes that approached but did not achieve statistical significance, which may reflect the lower expression of GSK-3β-his in this line. To rule out an effect of overt changes in the state of the mice that could confound the exploratory behavior assessment, data for total activity were collected in the hole board arena. No significant differences were found among the WT, WT with lithium, PrpGsk3b, and PrpGsk3b with lithium groups (Figure (Figure2D). 2D).

Heterozygous loss of Gsk3b causes behavioral defects that mimic lithium action, including reduced time immobile in the FST and reduced exploratory behavior (20, 43); we found that transgenic expression of Gsk3b in Gsk3b+/– heterozygotes reversed these behavioral defects, demonstrating that the behavioral defects observed in Gsk3b+/– mice are also specifically due to Gsk3b loss of function (Supplemental Results and Supplemental Figure 4).

Gsk3b is required for the β-arrestin-2/Akt/PP2A complex.

Previous work has defined a central role for β-arrestin-2 as a molecular scaffold that binds Akt and PP2A in neurons of the striatum to mediate dephosphorylation of Akt and, indirectly, reactivation of GSK-3. This complex is disrupted by lithium in striatal homogenates (13). Lithium also inhibits the in vitro interaction of recombinant β-arrestin-2 and Akt, although at a relatively high concentration of lithium (50 mM). Earlier work has shown that GSK-3 is also a component of the complex (44); we therefore tested whether GSK-3 contributes to the stability of the β-arrestin-2 complex. We isolated striata from WT mice, immunoprecipitated AKT, and blotted for components of the complex. Under basal conditions, Akt, PP2A, β-arrestin-2, GSK-3α, and GSK-3β interacted in the striatum, and association of Akt, PP2A, and β-arrestin-2 was disrupted by LiCl (Figure (Figure3,3, A–C), as previously published (13, 44, 45). If GSK-3 stabilizes this complex, then structurally distinct GSK-3 inhibitors should mimic lithium and disrupt the complex. Indeed, addition of the GSK-3 inhibitors 6BIO (Figure (Figure3A)3A) or AR-A014418 (Supplemental Results and Supplemental Figure 6) to the immunoprecipitations disrupted interaction of Akt with β-arrestin-2 and PP2A (Figure (Figure3A),3A), similar to LiCl. We also note that the level of GSK-3α/β in the Akt immunoprecipitates is not reduced upon inhibition, perhaps reflecting additional Akt/GSK-3–containing complexes that are not sensitive to GSK-3 inhibition (4650). To confirm that the β-arrestin-2 complex is sensitive to GSK-3 inhibitors, we performed immunoprecipitations from striatum using an anti–β-arrestin-2 antibody. Consistent with Figure Figure3A3A and prior reports, β-arrestin-2 interacted with PP2A (13, 44, 45), and addition of lithium or 6BIO disrupted this interaction (Figure (Figure3B).3B). The β-arrestin-2 immunoprecipitates also contained Akt and GSK-3α/β, but we did not observe dissociation of Akt or GSK-3 when GSK-3 was inhibited; while the reasons for this are unclear, each of these signaling molecules are known to associate in multiple and distinct complexes (4650), and the β-arrestin antibody used here may identify additional complexes that are not sensitive to GSK-3 inhibition.

Figure 3
GSK-3 stabilizes the β-arrestin-2/Akt/ PP2A/GSK-3 complex.

These observations suggest that GSK-3 contributes to β-arrestin-2 complex stability and that lithium disrupts the β-arrestin scaffold in vivo by inhibiting GSK-3, in addition to the reported direct effect on β-arrestin-2/Akt interaction. To investigate whether GSK-3 regulates the β-arrestin-2 complex in vivo, we also tested complex formation in the striatum of Gsk3b+/– mice and found reduced interaction of Akt and PP2A in mice lacking one copy of Gsk3b (Figure (Figure3,3, C and D). WT and PrpGsk3bL56 mice were also treated for 12 days with LiCl, as above. Chronic LiCl reduced interaction between Akt and PP2A in WT mice, as reported previously (13), and this was restored in PrpGsk3bL56 mice (Figure (Figure3,3, C and D). Taken together, these observations show that the β-arrestin-2/Akt/PP2A/GSK-3 complex requires GSK-3, as both pharmacologic and genetic interference with Gsk3b disrupts complex formation and, importantly, overexpression of Gsk3b restores complex formation in parallel with the rescue of lithium-sensitive behaviors.


Defining the direct molecular target of lithium is critically important for the development of new drugs to treat BPD and to define the molecular pathogenesis of this common psychiatric disease. We have proposed a set of criteria to validate a putative target of lithium that can be applied in each lithium-sensitive context (5), including (a) in vivo inhibition, (b) pharmacologic evidence that structurally diverse inhibitors mimic lithium, (c) genetic evidence through mutation of the target, and (d) reversal of lithium-sensitive behaviors by restoring activity of the target in the presence of lithium.

Each of these criteria is now fulfilled for GSK-3: GSK-3 is inhibited by lithium in the rodent brain (16, 20, 30, 31); diverse GSK-3 inhibitors mimic lithium action in multiple behaviors (13, 3437); deletion of Gsk3a or Gsk3b mimics lithium action in mouse behaviors (13, 20, 34); and, as shown here, lithium-sensitive behaviors (and dissociation of the β-arrestin-2 complex) were reversed by raising Gsk3 expression in the brain, demonstrating that these actions of lithium are specifically and causally related to GSK-3 inhibition.

Applying these criteria to validate GSK-3 in the therapy of BPD is more challenging, but early data are encouraging. GSK-3 N-terminal phosphorylation, a marker for GSK-3 inhibition, is increased in PBMCs from patients with BPD treated with lithium (51) and is reduced in PBMCs of untreated patients with BPD compared with that of healthy controls, implying increased baseline GSK-3 activity (33). Furthermore, olanzapine, an alternative medication for BPD, has also been reported to be a direct GSK-3 inhibitor (52). The observation that a structurally distinct GSK-3 inhibitor may have similar therapeutic actions as lithium supports the hypothesis that GSK-3 is the therapeutically relevant target of lithium in the treatment of BPD.

Other GSK-3 transgenic mouse lines have been reported, but these were not tested for reversal of lithium-sensitive behaviors (30, 53, 54). Interestingly, overexpression of the phosphorylation-defective GSK-3βS9A increases locomotor activity, which was interpreted as a manic-like state (53). Similarly, knockin mice in which N-terminal phosphorylation sites in Gsk3a and Gsk3b were mutated to alanine, preventing inhibitory phosphorylation, show hyperlocomotion in a novel environment (33, 55), enhanced locomotor response to amphetamine, increased immobility in the FST and tail suspension test, and reduced time in the open arms of the elevated plus maze (33). All of these behaviors are opposite to the behaviors observed with lithium or Gsk3b haploinsufficiency and are therefore consistent with GSK-3 as the relevant target of lithium in these behaviors. It should be pointed out, however, that Ackermann et al. observed reduced immobility in the FST and increased time in the open arms of the EZM (55); although the hyperactivity of the mice in their study may make it difficult to interpret increased swimming activity in the FST, nevertheless the reason for the differences between these 2 studies is not clear, as both groups used mice on a similar, albeit mixed, genetic background.

Many lithium-sensitive behaviors in mice require β-arrestin-2, and assembly in the striatum of a complex that includes β-arrestin-2, Akt, and PP2A is sensitive to lithium. β-Arrestin-2 recruits PP2A to dephosphorylate and inactivate Akt (Figure (Figure4).4). As Akt phosphorylates and inactivates GSK-3, assembly of this complex is predicted to enhance GSK-3 activity. Lithium interferes with stability of this β-arrestin complex, and, by preventing PP2A-dependent dephosphorylation of Akt, enhances Akt-mediated inhibition of GSK-3. This model is strongly supported by the observations that either β-arrestin-2 knockout or lithium enhances GSK-3 phosphorylation in vivo. However, while lithium can disrupt the direct interaction of recombinant β-arrestin-2 and Akt, this was done in the presence of 50 mM lithium, and whether interaction of the purified proteins is sensitive to more therapeutically relevant lithium concentrations has not been reported. Alternatively, we propose that GSK-3 plays a functional role in complex stability. In support of this hypothesis, structurally diverse GSK-3 inhibitors disrupted the β-arrestin-2 complex in striatal extracts, loss of one copy of Gsk3b also disrupted the complex in vivo, and overexpression of Gsk3b restored complex formation in the presence of lithium. These data show that GSK-3 is required in vivo and in vitro for the stability of this complex (Figure (Figure4A)4A) and support the hypothesis that direct inhibition of GSK-3 by lithium contributes substantially to disassembly of the β-arrestin-2/Akt/PP2A complex (Figure (Figure4B). 4B).

Figure 4
Model for lithium action and GSK-3 stabilization of the β-arrestin-2/Akt/ PP2A/GSK-3 complex.

The IC50 for lithium inhibition of GSK-3 is approximately 1 mM, at the high end of the therapeutic window for lithium therapy. However, lithium treatment enhances inhibitory phosphorylation of GSK-3, both in vivo and in cell culture, and this has been proposed to amplify the in vivo response to lithium in target tissues (31, 56). Thus, GSK-3 plays a positive role in its own activation by promoting activation of a phosphatase that removes N-terminal inhibitory phosphate groups on GSK-3 (57) and by promoting dephosphorylation and inhibition of Akt by stabilizing β-arrestin-2/Akt/PP2A interaction in the striatum. Lithium, through direct inhibition of GSK-3, blocks both mechanisms of autoactivation of GSK-3, providing at least two mechanisms to enhance lithium inhibition of GSK-3 in a tissue-dependent manner. Conversely, sensitivity to lithium is markedly affected by the level of GSK-3, and small increases in GSK-3 expression can therefore attenuate sensitivity to lithium, as shown here and discussed previously (57).

While the behavioral effects of Gsk3b haploinsufficiency reported here and in prior work from this and other groups are highly concordant, one group reported that they were unable to observe behavioral phenotypes in Gsk3b+/– mice (58). However, these behaviors were tested in mice with a mixed genetic background that included the 129 strain, whereas the mice in this study and in the work of Beaulieu et al. were backcrossed into the C57BL/6 background (13). In this context, it should be noted that 129 mice are insensitive to lithium in amphetamine-induced hyperlocomotion, whereas C57BL/6 mice are highly sensitive (59), an intriguing observation that deserves further study, as it may help to explain the variable response to lithium in patients with BPD.

In summary, we have shown that overexpression of Gsk3b rescues the behavioral phenotypes observed in Gsk3b heterozygotes and lithium-treated mice and that direct inhibition of GSK-3 by lithium destabilizes the interaction of β-arrestin-2/Akt/PP2A in the striatum. Taken together with prior work using alternative GSK-3 inhibitors and genetic studies using both loss of function and knockin of constitutively active forms Gsk3, these findings provide strong support for GSK-3 as the relevant target of lithium in animal behaviors. Important questions to address in future work are how GSK-3 regulates these behaviors at a molecular level and, importantly, in which neuronal populations is GSK-3 function important for regulating these behaviors.


Generation of transgenic mice.

The Gsk3b transgene was generated with Xenopus Gsk3b (93% identical to mouse and human Gsk3b and 97% similar to mouse and human Gsk3b; ref. 27), provided by David Kimelman (University of Washington, Seattle, Washington, USA), and driven by the mouse prion promoter (MoPrP.Xho; gift of David Borchelt, Johns Hopkins University, Baltimore, Maryland, USA) (39, 60). A 6X-his tag was added to the C terminus to distinguish endogenous from transgenic GSK-3β. Linearized plasmid was purified and injected into C57B6/129 heterozygous blastocysts by the University of Pennsylvania Transgenic and Chimeric Mouse Facility for generation of mice. Two founders were used to establish distinct lines, PrpGsk3bL56 and PrpGsk3bL64, which were backcrossed into the C57/B6 strain for more than 10 generations. Both transgenic lines had normal litter sizes, and the transgene was transmitted in normal Mendelian fashion. Tissue from 3-month-old mice of each line was harvested for molecular analysis. Several brain regions were microdissected, and transgene expression was confirmed for both lines by RT-PCR. Transgenic protein expression was assessed by Western blot for the C-terminal his tag and for GSK-3β. Inositol levels were similar in the cortex, striatum, and hippocampus of WT, PrpGsk3bL56, and PrpGsk3bL64 mice (Supplemental Methods, Supplemental Results, and Supplemental Figure 3).

Mice were housed 2 to 3 per cage, segregated by gender, in a 12-hour-light/dark cycle. No overt changes in home cage behavior were observed, including overall activity, grooming, and social interactions. At 10 to 12 weeks, mice were randomly assigned to experimental and control groups. All animal experimentation was reviewed and approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania and the University of Pennsylvania Laboratory Animal Resource Committee.

Behavioral testing.

In regard to strain background, behavioral analysis was initially performed in mice backcrossed a minimum of 5 to 10 generations into C57/B6; all behavioral data were confirmed in a larger cohort backcrossed more than 10 generations into C57/B6. Porsolt FST, hole board exploratory behavior, and EZM were performed, as described previously (20), on days 7, 9, and 11 of lithium treatment. The order of the respective tests was varied to avoid an order effect.

Lithium dosing and testing schedule.

Control and transgenic mice were allowed free access to water and standard mouse chow throughout the experiment. For lithium treatment, mice were fed 0.2% (w/w) LiCl mouse chow (Harlan Teklad) ad lib for 3 days, followed by 0.4% (w/w) LiCl mouse chow for the duration of the experiment (20). All mice had access to supplemental 450 mM NaCl drinking solution.

Immunoblotting and immunoprecipitations.

Frontal cortex, hippocampus, hypothalamus, striatum, nucleus accumbens, amygdala, olfactory bulb, and cerebellum were harvested on day 12 of lithium treatment, frozen in liquid nitrogen, and stored at –80°C. All behavior experiments and tissue harvest took place between 8:00 AM and 12:30 PM. Antibodies to GSK-3β (N terminus) and β-catenin were from BD Transduction Laboratories. Antibodies to glycogen synthase, phosphorylated glycogen synthase (GSS641P), and Akt were from Cell Signaling Technology. Anti–β-arrestin-2 antibodies were from Cell Signaling Technology. Anti–β-tubulin antibodies were from Promega. Frozen samples of dissected brain regions were homogenized with a Polytron PT10-35 Tissue Homogenizer in 200 μl 0.75% NP-40 lysis buffer (61). Protein content was determined by Bradford assay. Samples from individual animals (5–10 μg per lane) were analyzed by SDS-PAGE and immunoblotting. Immunoblots were visualized by ECL or ECL plus (Amersham). To measure band intensity in immunoblots, filters were probed with infrared-labeled secondary antibodies (Rockland Inc.), imaged with a LI-COR Odyssey Infrared Imager according to the manufacturer’s instructions, and quantitated using LI-COR software (LI-COR Biosciences). For immunoprecipitations, striatal lysates were prepared as above and pooled from 3 mice per group. One mg of striatal lysate was used for immunoprecipitation with an antibody to Akt immobilized on sepharose beads (Cell Signaling Technology). Immunoprecipitation was conducted overnight at 4°C, followed by immunoblotting with an anti-PP2A antibody (Cell Signaling Technology).


A 1-tailed Student’s t test was performed on all behaviors to test for gender differences. No significant gender differences were found so the data were combined. For all other data, a 1-way ANOVA was used, followed by Dunn’s post-hoc analysis when a significant difference was found among groups. The level of significance was set at P < 0.05. Histograms show mean values ± SEM throughout.

Supplementary Material

Supplemental data:


We thank all members of the Klein laboratory for discussions and comments on the manuscript and Amber DeAra Harper and Robert Fagan for technical assistance. We thank Morrie Birnbaum and his laboratory for use of the LI-COR, David Hurtado, and Virginia MY Lee for help with GSK-3 assays, David Borchelt for providing the MoPrp.xho plasmid, and David Kimelman for the XGSK3b plasmid. This work was supported by grants to P.S. Klein from the National Institute of Mental Health (1RO1MH58324) and from the American Federation for Aging Research. J. Huang was supported by the Leukemia and Lymphoma Society. A.J. Valvezan received support from the Training Program in Neuropsychopharmacology (T32 MH14654-33). G.T. Berry was supported by the Manton Center for Orphan Disease Research.


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2011;121(9):3756–3762. doi:10.1172/JCI45194.


1. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist. 2002;8(5):497–511. doi: 10.1177/107385802237176. [PubMed] [Cross Ref]
2. Cade J. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–352. [PubMed]
3. Schou M. Lithium treatment at 52. J Affect Disord. 2001;67(1–3):21–32. doi: 10.1016/S0165-0327(01)00380-9. [PubMed] [Cross Ref]
4. Pilcher HR. Drug research: the ups and downs of lithium. Nature. 2003;425(6954):118–120. doi: 10.1038/425118a. [PubMed] [Cross Ref]
5. O’Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. 2009;37(Pt 5):1133–1138. doi: 10.1042/BST0371133. [PMC free article] [PubMed] [Cross Ref]
6. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989;59(3):411–419. doi: 10.1016/0092-8674(89)90026-3. [PubMed] [Cross Ref]
7. York JD, Guo S, Odom AR, Spiegelberg BD, Stolz LE. An expanded view of inositol signaling. Adv Enzyme Regul. 2001;41:57–71. doi: 10.1016/S0065-2571(00)00025-X. [PubMed] [Cross Ref]
8. Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol Ther. 2002;96(1):45–66. doi: 10.1016/S0163-7258(02)00299-1. [PubMed] [Cross Ref]
9. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002;417(6886):292–295. doi: 10.1038/417292a. [PubMed] [Cross Ref]
10. Tanizawa Y, Kuhara A, Inada H, Kodama E, Mizuno T, Mori I. Inositol monophosphatase regulates localization of synaptic components and behavior in the mature nervous system of C. elegans. Genes Dev. 2006;20(23):3296–3310. doi: 10.1101/gad.1497806. [PubMed] [Cross Ref]
11. Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22(1):62–65. doi: 10.1097/00043426-200001000-00012. [PubMed] [Cross Ref]
12. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455–8459. doi: 10.1073/pnas.93.16.8455. [PubMed] [Cross Ref]
13. Beaulieu JM, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008;132(1):125–136. doi: 10.1016/j.cell.2007.11.041. [PubMed] [Cross Ref]
14. Hedgepeth C, Conrad L, Zhang Z, Huang H, Lee V, Klein P. Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol. 1997;185(1):82–91. doi: 10.1006/dbio.1997.8552. [PubMed] [Cross Ref]
15. Stambolic V, Ruel L, Woodgett J. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6(12):1664–1668. doi: 10.1016/S0960-9822(02)70790-2. [PubMed] [Cross Ref]
16. Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer’s disease-like tau protein phosphorylation in neurons. FEBS Lett. 1997;411(2–3):183–188. doi: 10.1016/S0014-5793(97)00688-1. [PubMed] [Cross Ref]
17. Hong M, Chen DC, Klein PS, Lee VM-Y. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem. 1997;272(40):25326–25332. doi: 10.1074/jbc.272.40.25326. [PubMed] [Cross Ref]
18. Lovestone S, Hartley CL, Pearce J, Anderton BH. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. NeuroScience. 1996;73(4):1145–1157. doi: 10.1016/0306-4522(96)00126-1. [PubMed] [Cross Ref]
19. Mudher A, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry. 2004;9(5):522–530. doi: 10.1038/ [PubMed] [Cross Ref]
20. O’Brien WT, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J NeuroSci. 2004;24(30):6791–6798. doi: 10.1523/JNEUROSCI.4753-03.2004. [PubMed] [Cross Ref]
21. Meijer L, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. 2003;10(12):1255–1266. [PubMed]
22. Hedgepeth CM, Deardorff MA, Rankin K, Klein PS. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol. 1999;19(10):7147–7157. [PMC free article] [PubMed]
23. Williams DS, Atilla GE, Bregman H, Arzoumanian A, Klein PS, Meggers E. Switching on a signaling pathway with an organoruthenium complex. Angew Chem Int Ed Engl. 2005;44(13):1984–1987. doi: 10.1002/anie.200462501. [PubMed] [Cross Ref]
24. Harwood AJ, Plyte SE, Woodgett J, Strutt H, Kay RR. Glycogen synthase kinase 3 regulates cell fate in Dictyostelium. Cell. 1995;80(1):139–148. doi: 10.1016/0092-8674(95)90458-1. [PubMed] [Cross Ref]
25. Cohen ED, et al. Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. J Clin Invest. 2007;117(7):1794–1804. doi: 10.1172/JCI31731. [PMC free article] [PubMed] [Cross Ref]
26. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. 2007;12(6):957–971. doi: 10.1016/j.devcel.2007.04.001. [PubMed] [Cross Ref]
27. Pierce SB, Kimelman D. Regulation of Spemann organizer formation by the intracellular kinase Xgsk-3. Development. 1995;121(3):755–765. [PubMed]
28. He X, Saint-Jeannet J-P, Woodgett JR, Varmus HE, Dawid IB. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature. 1995;374(6523):617–622. doi: 10.1038/374617a0. [PubMed] [Cross Ref]
29. Dominguez I, Itoh K, Sokol SY. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. . Proc Natl Acad Sci U S A. 1995;92(18):8498–8502. doi: 10.1073/pnas.92.18.8498. [PubMed] [Cross Ref]
30. Noble W, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005;102(19):6990–6995. doi: 10.1073/pnas.0500466102. [PubMed] [Cross Ref]
31. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002;43(7):1158–1164. doi: 10.1016/S0028-3908(02)00215-0. [PubMed] [Cross Ref]
32. Li X, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61(2):216–222. doi: 10.1016/j.biopsych.2006.02.027. [PMC free article] [PubMed] [Cross Ref]
33. Polter A, et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology. 2010;35(8):1761–1774. [PMC free article] [PubMed]
34. Beaulieu JM, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 2004;101(14):5099–5104. doi: 10.1073/pnas.0307921101. [PubMed] [Cross Ref]
35. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004;7(4):387–390. doi: 10.1017/S1461145704004535. [PubMed] [Cross Ref]
36. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry. 2004;55(8):781–784. doi: 10.1016/j.biopsych.2004.01.008. [PubMed] [Cross Ref]
37. Weiner I, Schiller D, Gaisler-Salomon I, Green A, Joel D. A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine. Behav Pharmacol. 2003;14(3):215–222. doi: 10.1097/00008877-200305000-00005. [PubMed] [Cross Ref]
38. Beaulieu JM, Caron MG. Looking at lithium: molecular moods and complex behaviour. Mol Interv. 2008;8(5):230–241. doi: 10.1124/mi.8.5.8. [PubMed] [Cross Ref]
39. Borchelt DR, et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13(6):159–163. [PubMed]
40. Ma T, et al. Statin’s excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via rho-ROCK signaling. J Neurosci. 2009;29(36):11226–11236. doi: 10.1523/JNEUROSCI.6150-08.2009. [PMC free article] [PubMed] [Cross Ref]
41. Goñi-Oliver P, Lucas JJ, Avila J, Hernández F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem. 2007;282(31):22406–22413. doi: 10.1074/jbc.M702793200. [PubMed] [Cross Ref]
42. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229(2):327–336. [PubMed]
43. Beaulieu JM, et al. Reply to Belmaker et al.: GSK3 haploinsufficiency results in lithium-like effects in the forced-swim test. Proc Natl Acad Sci U S A. 2008;105(20):E24.
44. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261–273. doi: 10.1016/j.cell.2005.05.012. [PubMed] [Cross Ref]
45. Beaulieu JM, et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J NeuroSci. 2007;27(4):881–885. doi: 10.1523/JNEUROSCI.5074-06.2007. [PubMed] [Cross Ref]
46. Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell. 2009;17(4):443–458. doi: 10.1016/j.devcel.2009.09.011. [PMC free article] [PubMed] [Cross Ref]
47. DeFea KA. Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold? Cell Signal. 2011;23(4):621–629. doi: 10.1016/j.cellsig.2010.10.004. [PubMed] [Cross Ref]
48. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116(pt 7):1175–1186. [PMC free article] [PubMed]
49. Sim AT, Scott JD. Targeting of PKA, PKC and protein phosphatases to cellular microdomains. Cell Calcium. 1999;26(5):209–217. doi: 10.1054/ceca.1999.0072. [PubMed] [Cross Ref]
50. Kikuchi A. Roles of axin in the Wnt signalling pathway. Cell Signal. 1999;11(11):777–788. doi: 10.1016/S0898-6568(99)00054-6. [PubMed] [Cross Ref]
51. Li X, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61(2):216–222. doi: 10.1016/j.biopsych.2006.02.027. [PMC free article] [PubMed] [Cross Ref]
52. Mohammad MK, et al. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation. Eur J Pharmacol. 2008;584(1):185–191. doi: 10.1016/j.ejphar.2008.01.019. [PubMed] [Cross Ref]
53. Prickaerts J, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J NeuroSci. 2006;26(35):9022–9029. doi: 10.1523/JNEUROSCI.5216-05.2006. [PubMed] [Cross Ref]
54. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation, and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20(1–2):27–39. doi: 10.1093/emboj/20.1.27. [PubMed] [Cross Ref]
55. Ackermann TF, Kempe DS, Lang F, Lang UE. Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell Physiol Biochem. 2010;25(6):775–786. doi: 10.1159/000315097. [PubMed] [Cross Ref]
56. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A. 1999;96(15):8745–8750. doi: 10.1073/pnas.96.15.8745. [PubMed] [Cross Ref]
57. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem. 2003;278(35):33067–33077. doi: 10.1074/jbc.M212635200. [PubMed] [Cross Ref]
58. Bersudsky Y, Shaldubina A, Kozlovsky N, Woodgett JR, Agam G, Belmaker RH. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav Pharmacol. 2008;19(3):217–224. doi: 10.1097/FBP.0b013e3282feb099. [PubMed] [Cross Ref]
59. Gould TD, O’Donnell KC, Picchini AM, Manji HK. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology. 2007;32(6):1321–1333. doi: 10.1038/sj.npp.1301254. [PubMed] [Cross Ref]
60. Sasaki Y, Vohra BP, Baloh RH, Milbrandt J. Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. . J NeuroSci. 2009;29(20):6526–6534. doi: 10.1523/JNEUROSCI.1429-09.2009. [PMC free article] [PubMed] [Cross Ref]
61. Tao YS, Edwards RA, Tubb B, Wang S, Bryan J, McCrea PD. beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. J Cell Biol. 1996;134(5):1271–1281. doi: 10.1083/jcb.134.5.1271. [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation